Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CEO post at Genevant
→ Gurnet Point Capital-backed Auregen BioTherapeutics has tapped Amgen vet Richard Davies to lead its rare disease cell therapy’s entry into the clinic as CEO. Davies, a former Hospira chief commercial officer who had his first chief executive experience recently at Bonesupport, will lead the drive in translating the Geneva-based biotech’s 3D biofabrication technologies to new therapeutics, starting from a program in rare congenital craniofacial disorders.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters